Securities code: 600807 securities abbreviation: Jinan High-Tech Development Co.Ltd(600807) Announcement No.: pro 2022-014 Jinan Chengdu Hi-Tech Development Co.Ltd(000628) Co., Ltd
About the acquisition of Shandong aikewei Biotechnology Co., Ltd. by a wholly-owned subsidiary
Announcement on the completion of transfer of some equity
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
The company held the 23rd extraordinary meeting of the 10th board of directors on December 7, 2021 and the fourth extraordinary general meeting of shareholders in 2021 on December 27, 2021, and deliberated and adopted the proposal on the acquisition of part of the equity and related transactions of Shandong aikewei Biotechnology Co., Ltd. by its subsidiaries, The company's wholly-owned subsidiary Jinan High-Tech Development Co.Ltd(600807) Industrial Development Co., Ltd. (hereinafter referred to as "Jigao industry") contributed 228.65 million yuan, the related party Jinan High-Tech Development Co.Ltd(600807) Financial Investment Co., Ltd. contributed 139.2 million yuan and Jinan High-Tech Development Co.Ltd(600807) Shenghe Development Co., Ltd. contributed 136.15 million yuan, A total of 60% of the equity of Shandong aikewei Biotechnology Co., Ltd. (hereinafter referred to as "aikewei biotechnology") held by Xilong Scientific Co.Ltd(002584) (hereinafter referred to as " Xilong Scientific Co.Ltd(002584) ") will be acquired. After this acquisition, Jigao industry will hold 27.2202% of the equity of aikewei biotechnology. At the same time, Xilong Scientific Co.Ltd(002584) will remove the income right and All rights other than the disposal right (except the disposal caused by the failure to reach the performance commitment compensation) are unconditionally and irrevocably entrusted to Jigao industry for exercise. After the completion of this acquisition, aikewei biology will be included in the scope of the company's consolidated statements. See the relevant announcements disclosed by the company on December 3, December 8 and December 11, 2021 for details.
On February 16, 2022, aikewei biological went through the industrial and commercial registration procedures for the equity transfer and obtained the business license issued by the Management Committee of Jinan High-Tech Development Co.Ltd(600807) technology industry development zone.
Before and after the equity transfer, the equity structure of aikewei biology is shown in the following table:
Before and after change
Shareholder name contribution proportion shareholder name contribution proportion
Jinan High-Tech Development Co.Ltd(600807) Industrial Development Co., Ltd. 27.2202% Jinan High-Tech Development Co.Ltd(600807) Shenghe Development Co., Ltd. 16.2084% Xilong Scientific Co.Ltd(002584) 73.7801% Jinan High-Tech Development Co.Ltd(600807) Financial Investment Co., Ltd. 16.5714% Xilong Scientific Co.Ltd(002584) 13.7801%
Zhang Guoning 16.2125%
Jinan xinlijing biotechnology partnership 8.1225% Jinan xinlijing biotechnology partnership 8.1225% industry (limited partnership) industry (limited partnership)
Jiang Peipei 1.4998%
Zhang Shulan 0.3851%
Total 100% total 100%
The information disclosure media designated by the company are Shanghai Securities News, China Securities News and the website of Shanghai Stock Exchange. The information about the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to investment risks. It is hereby announced.
Jinan Chengdu Hi-Tech Development Co.Ltd(000628) Co., Ltd
Board of directors
February 17, 2022
